



This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you experience. You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.

AUSTRALIAN PRODUCT INFORMATION – AVOMI FLIQ PODS (NICOTINE BENZOATE) INHALATION PODS

1. NAME OF THE MEDICINE

AVOMI FLIQ PODS

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each 2 mL pod contains:

- Nicotine 20 mg/mL

Available in Tobacco, Menthol, and Mint variants. These flavours are formulated using proprietary flavouring components compliant with TGO 110 & TGO 100. All flavouring ingredients are disclosed to the TGA and approved for use in nicotine vaping products. No prohibited substances are included.

Nicotine is present as nicotine benzoate in a propylene glycol and vegetable glycerin base.

3. PHARMACEUTICAL FORM

Inhalation liquid in sealed 2 mL pods for use in a compatible closed system vaping device. Clear to pale yellow liquid.

4. CLINICAL PARTICULARS

4.1. Therapeutic Indications

AVOMI FLIQ PODS are indicated for use in adult patients as part of a medically supervised program to support smoking cessation or assist in the reduction of nicotine consumption.

Unlike tobacco smoking, nicotine vaping products do not involve combustion and therefore avoid exposure to harmful by-products generated through burning tobacco [1].

4.2. Dose and Method of Administration

Use as directed by a healthcare professional. Administer via the compatible AVOMI DEVICE.

4.3. Contraindications

Hypersensitivity to nicotine or any ingredient in the formulation.

4.4. Special Warnings and Precautions for Use

- Use with caution in patients with cardiovascular disease, diabetes, or seizure disorders.
- Not recommended for non-smokers, adolescents, pregnant or breastfeeding women unless the benefits outweigh risks. Nicotine vaping products avoid exposure to combustion-related toxins but the long-term safety of inhaled nicotine and flavourings is not fully established [1].
- Keep out of reach of children. Accidental ingestion may be harmful or fatal.

4.5. Interaction with Other Medicines and Other Forms of Interaction

Nicotine may interact with theophylline, insulin, and other medications [2, 3]. Monitor patients closely.

4.6. Fertility, Pregnancy and Lactation

Not recommended during pregnancy or breastfeeding unless the benefits outweigh risks. Use under medical supervision.

4.7. Effects on Ability to Drive and Use Machines

No known effects. Patients should assess individual response before operating machinery.

4.8. Undesirable Effects

Common: throat irritation, cough, dry mouth.
Rare: palpitations, nausea, dizziness.

4.9. Overdose

Symptoms: nausea, vomiting, salivation, abdominal pain, diarrhoea. In severe cases, seizures or coma. Seek medical help immediately.

5. PHARMACOLOGICAL PROPERTIES

5.1. Pharmacodynamic Properties

Nicotine is an agonist at nicotinic acetylcholine receptors, reducing withdrawal symptoms and cravings.

5.2. Pharmacokinetic Properties

Absorbed through the lungs, peak plasma levels achieved within minutes. Metabolised in liver; excreted via urine.

5.3. Preclinical Safety Data

Animal studies indicate that nicotine exposure during prenatal and adolescent periods may disrupt neurodevelopment, particularly during critical stages of brain maturation. The long-term safety of inhaled nicotine in humans remains under investigation [4, 5].

6. PHARMACEUTICAL PARTICULARS

6.1. List of Excipients

Propylene glycol, vegetable glycerin, flavourings.

6.2. Incompatibilities

Not applicable.

6.3. Shelf Life

24 months from date of manufacture.

6.4. Special Precautions for Storage

Store below 25°C, away from moisture, heat or sunlight. Keep out of reach of children. Do not use if pod is damaged or leaking.

6.5. Nature and Contents of Container

Pack of 2 x 2 mL sealed pods.

6.6. Special Precautions for Disposal

Dispose of used pods in accordance with local regulations. Do not puncture or incinerate. Return unused products to any pharmacy.

7. MEDICINE SCHEDULE (POISONS STANDARD)

- AVOMI FLIQ PODS 20 mg/mL:
 - Schedule 3 – Pharmacist Only Medicine

8. LABELLING REQUIREMENTS

- KEEP OUT OF REACH OF CHILDREN
- Pharmacist Only Medicine (for S3 classifications)
- Prescription Only Medicine (for S4 classifications)
- Nicotine concentration clearly stated
- Ingredient listing for each variant
- Batch number
- Expiry date
- Storage conditions: Store below 25°C. Do not use after the expiry date.

9. INGREDIENTS

Available in Tobacco, Menthol, and Mint variants. Formulations contain a base of Propylene Glycol and Vegetable Glycerin, with proprietary flavourings approved under TGO 110 and TGO 100. No Schedule 1 prohibited ingredients are used.

10. PACKAGING

AVOMI FLIQ PODS are sealed in tamper-evident and child-resistant 2 mL pod units, compliant with TGO 110 and TGO 95.

11. RECORD KEEPING AND QUALITY ASSURANCE

Sponsor maintains batch records, certificates of analysis, and distribution logs in accordance with TGO 110 and the Therapeutic Goods Act 1989.

12. SPONSOR

CC Supplies Pty Ltd ABN: 51 166 955 602
Address: 25/1 Porter Street, Byron Bay
NSW, 2481, Australia

Prepared: June 2026 | Version 1.4

References

- [1] Therapeutic Goods Administration. *Nicotine Vaping Product Analysis: Evidence from the University of Wollongong* [Internet]. Canberra: Australian Government Department of Health; 2022 [cited 2025 May 19]. Available from: <https://www.tga.gov.au/sites/default/files/2022-11/nicotine-vaping-products-analysis-evidence-university-wollongong.pdf>
- [2] Benowitz NL. Pharmacologic aspects of cigarette smoking and nicotine addiction. *N Engl J Med*. 1988;319(20):1318–30.
- [3] Attvall S, Fowelin J, Lager I, Von Schenck H, Smith U. Smoking induces insulin resistance—a potential link with the insulin resistance syndrome. *J Intern Med*. 1993;233(4):327–32.
- [4] Drzewiecki CM, Sharma A, Tait RJ, Zubieta JK. Repeated exposure to high-dose nicotine induces prefrontal gray matter volume loss and behavioral deficits in adolescent rats. *Neuroscience*. 2023;527:1–12.
- [5] Sulaimon RJ, Alagbonsi IA, Hamzat TA, Salahdeen HM. Prenatal exposure to gestational nicotine before neurulation is detrimental to neurodevelopment of Wistar rats' offspring. *Malays J Med Sci*. 2024;31(2):45–56.